LivaNova PLC $LIVN Shares Purchased by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its stake in LivaNova PLC by 111.7%, owning approximately 2.88% of the company, worth about $60.8 million.
• LivaNova reported $1.05 earnings per share for the last quarter, exceeding analysts' expectations of $0.84 with a revenue increase of 10.6% year-over-year.
• Research analysts maintain a consensus rating of "Buy" for LivaNova, and the average price target among them is set at $59.71.

AQR Capital Management LLC boosted its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 111.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,571,295 shares of the company's stock after purchasing an additional 829,115 shares during the period. AQR Capital Management LLC owned about 2.88% of LivaNova worth $60,809,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC raised its stake in shares of LivaNova by 25.5% during the 4th quarter. Hsbc Holdings PLC now owns 5,876 shares of the company's stock worth $272,000 after buying an additional 1,193 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in LivaNova by 11.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,180 shares of the company's stock worth $1,722,000 after acquiring an additional 3,839 shares during the period. Northern Trust Corp grew its holdings in LivaNova by 11.2% during the fourth quarter. Northern Trust Corp now owns 703,019 shares of the company's stock worth $32,557,000 after acquiring an additional 70,630 shares during the period. AXA S.A. purchased a new position in LivaNova in the fourth quarter worth $1,662,000. Finally, BNP Paribas Financial Markets lifted its holdings in LivaNova by 22.8% in the fourth quarter. BNP Paribas Financial Markets now owns 34,185 shares of the company's stock valued at $1,583,000 after acquiring an additional 6,340 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

Shares of NASDAQ LIVN traded up $0.82 on Thursday, hitting $57.34. The company's stock had a trading volume of 414,292 shares, compared to its average volume of 586,619. The stock has a 50 day moving average of $49.63 and a 200-day moving average of $43.95. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -14.74 and a beta of 0.97. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $58.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. During the same period last year, the company posted $0.93 EPS. The company's revenue was up 10.6% on a year-over-year basis. As a group, research analysts predict that LivaNova PLC will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

LIVN has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price target on shares of LivaNova in a research note on Wednesday, September 3rd. Barclays boosted their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.